Cargando…
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
SIMPLE SUMMARY: It is estimated that 30–50 percent of patients treated with Immune Checkpoint Blockers will eventually develop cutaneous immune-related adverse events. These toxicities are in, most of the time, low-grade reactions; however, they are characterized by a wide clinical spectrum. Clinici...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093334/ https://www.ncbi.nlm.nih.gov/pubmed/37046745 http://dx.doi.org/10.3390/cancers15072084 |